2208-08-4

Basic information

• Product Name: ETHYL BUTYRIMIDATE HYDROCHLORIDE
• Synonyms: ethyl butanimidate hydrochloride;Ethyl butyrimidate hydrochloride >=97.0% (AT);butyrimidicacid,ethylester,hydrochloride;ethyl butanecarboximidate hydrochloride
• CAS NO: 2208-08-4
• Molecular Formula: C₆H₁₃NO*ClH
• Molecular Weight: 151.63446
• Mol File: 2208-08-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 74-79 °C
• Boiling Point: 114.4 °C at 760 mmHg
• Flash Point: 23 °C
• Appearance: /
• Vapor Pressure: 23.7mmHg at 25°C
• Storage Temp.: 2-8°C
• BRN: 3679641
• CAS DataBase Reference: ETHYL BUTYRIMIDATE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL BUTYRIMIDATE HYDROCHLORIDE(2208-08-4)
• EPA Substance Registry System: ETHYL BUTYRIMIDATE HYDROCHLORIDE(2208-08-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: ET7250000
• F: 3-10-21
• Hazardous Substances Data: 2208-08-4(Hazardous Substances Data)

Usage

General Description

ETHYL BUTYRIMIDATE HYDROCHLORIDE is a chemical compound that is commonly used in biochemistry and molecular biology research. It is a water-soluble carbodiimide crosslinker that is used to covalently link carboxyl groups to primary amines in proteins, peptides, and nucleic acids. ETHYL BUTYRIMIDATE HYDROCHLORIDE is often utilized in the production of antibody drug conjugates, protein labeling, and in the immobilization of enzymes. It is a versatile and widely used reagent that helps researchers to study and manipulate biological molecules in various applications.

InChI:InChI=1/C6H13NO.ClH/c1-3-5-6(7)8-4-2;/h7H,3-5H2,1-2H3;1H

Upstream product

• 109-74-0 propyl cyanide 
• 64-17-5 ethanol 

Downstream Products

• 105-54-4 butanoic acid ethyl ester 
• 99840-45-6 4-methyl-2-propyl-1H-benzimidazole 
• 554-68-7 triethylamine hydrochloride 
• 146650-89-7 ethyl 5-methyl-2-propyl-3H-imidazole-4-carboxylate 
• 1206697-02-0 (5-propyl-4H-1,2,4-triazol-3-ylmethyl)carbamic acid benzyl ester 
• 790631-35-5 N-(2H-Pyrazol-3-yl)-butyramidine 
• 437717-21-0 N'-(1-iminobutyl)-2-ethoxybenzohydrazide hydrochloride 
• 630099-88-6 N-benzylbutyramidine hydrochloride 
• 3020-81-3 butylamidine hydrochloride 

Relevant articles and documents

Preparation method of telmisartan intermediate

The invention relates to a preparation method of a telmisartan intermediate, namely 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid. The preparation method of the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid comprises the following steps: firstly, ethanol hydrochloride acts with butyronitrile and anhydrous hydrogen chloride within the range of 0-35 DEG C; the mixture obtained in the firststep reacts with 3-methyl-4-aminobenzoic acid and ice vinegar within the range of pH 5.0-11.0 at the controlled temperature of 10-40 DEG C, and an intermediate shown in the formula II is obtained; and then the intermediate shown in the formula II reacts with a sodium hypochlorite solution, and the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid is obtained. The intermediate preparation processis suitable for industrial production, and meanwhile the product quality is improved.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.